What Injective does
Injective is a layer 1 blockchain built with the Cosmos SDK and purpose-built for finance, offering a fully on-chain central limit order book as a native module rather than forcing every application to build its own matching engine or rely on automated market makers. That means derivatives platforms, spot exchanges and prediction markets built on Injective all share a common, MEV-resistant order book and shared liquidity layer, rather than fragmenting it across separate AMM pools.
The chain supports sub-second finality and near-zero gas fees, and it connects to the wider multi-chain world through IBC with the Cosmos ecosystem and bridges to Ethereum and Solana, letting assets and liquidity move in. Injective has also pushed into real-world asset tokenisation and built an EVM-compatible execution environment (inEVM) to make it easier for Ethereum-native developers to deploy without rewriting contracts in CosmWasm, its default smart contract environment.
Where INJ fits in
INJ is the network's staking and governance token, used to secure the chain via proof-of-stake and to vote on protocol upgrades and parameters. Injective runs a deflationary burn auction: a share of fees generated by dApps across the ecosystem gets pooled weekly and auctioned off for INJ, which is then burned, tying token scarcity directly to ecosystem-wide trading activity rather than just base-layer gas fees.
Risks worth knowing
Injective's core bet — that a shared on-chain order book beats AMM liquidity for serious trading — is reasonable but unproven at real scale; total value locked and daily volumes on Injective remain modest next to Ethereum L2s and even other Cosmos chains. The finance-specific design also means Injective competes directly with dYdX, another order-book-focused chain, along with a growing field of perp-DEX-optimised layer 1s and app-chains, all chasing the same relatively narrow pool of serious on-chain traders. Cosmos-ecosystem chains have historically struggled to pull developer mindshare away from Ethereum and Solana, and Injective's long-term value accrual depends on genuinely sticky trading volume showing up — something that's been slower to materialise than the technology roadmap suggested.